ECOG-ACRIN Cancer Research Group: ECOG
One study  reported the change in ECoG
parameters before and after using the Meniett device.
A total of forty (n=40) histopathologically confirmed stage II or III carcinoma of urinary bladder patients between age 18 to 80 years with ECOG
performance status a$?2 and compromised renal function were recruited in this study.
Patient characteristics (n=36) Group A:DTX Group B:nab-PTX (n=18) (n=18) Number of Number of Characteristic Patients (%) Patients (%) p Median Age (Range) 49 (41-67) 51 (39-63) 0.800 ECOG
PS 0 18 (100) 18 (100) 1.000 T2/3 16 (89) 16 (89) 1.000 N (+) 6 (33) 8 (44) 0.494 ER (+) 14 (78) 14 (78) 1.000 PgR (+) 12 (78) 9 (50) 0.310 TNBC 4 (22) 4 (22) 1.000 Ki67 7 (39) 12 (67) 0.095 [greater than or equal to]20% ECOG
Performance Status; ER:estrogen receptor; PgR: progesterone receptor; TNBC: triple-negative breast cancer Table 2.
[0.03535 X age(y)] + 0.6978(if ECOG
2-4) + [1.367 X log 10(LDH/ULN)] + 0.9393 X log10(WBC),
Baseline ctDNA, baseline cHGF, and ECOG
performance status most strongly predicted overall survival, said the investigators.
Hastalarin yas (<65 - [greater than or equal to]65 yil), cinsiyet, ECOG
performans durumu (0-1 - 2-3), sigara kullanimi, tedavi oncesindeki hemoglobin duzeyleri (<10 - [greater than or equal to]10 gr/dL), tumor diferansiyasyonu, musin komponent varligi ve metastaz bolgelerinin verileri retrospektif olarak tarandi.
These data sets also were compared with two common scales used to gauge physical status and overall health: the Eastern Cooperative Oncology Group Performance Status (ECOG
) and Karnofsky Performance Status (KPS) scales.
Expected risk factors were age, body mass index, stage of cirrhosis, grade of varices, ascites, history of HE, Eastern Cooperative Oncology Group (ECOG
) performance status, active bleeding, overnight procedure, procedure times, and laboratory findings.
In the first step, only the Eastern Cooperation Oncology Group (ECOG
) performance status was found to be associated with survival.
(12-18) As the intention of the trial was to test the stents in patients with a life expectancy over six months only patients without metastatic disease and a good performance status (ECOG
0-2) were included.
Brahmer maintains affiliation with the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG
) Thoracic Committee and Cancer Prevention Steering Committee, American Association for Cancer Research, and International Association for the Study of Lung Cancer (IASLC).